Browsing by Author "Gabe, Rhian"

Now showing items 1-2 of 2

2017-05-12Zeitschriftenartikel

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

Osman, Mohamed; Mistry, Anoop; Keding, Ada; Gabe, Rhian; Cook, Elizabeth; Forrester, Sarah; Wiggins, Rebecca; Marco, Stefania Di; Colloca, Stefano; Siani, Loredana; Cortese, Riccardo; Smith, Deborah F.; Aebischer, Toni; Kaye, Paul M.

Background: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin ...
2021-07-07Zeitschriftenartikel

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan

Younis, Brima M.; Osman, Mohamed; Khalil, Eltahir A.G.; Santoro, Francesco; Furini, Simone; Wiggins, Rebecca; Keding, Ada; Carraro, Monica; Musa, Anas E.A.; Abdarahaman, Mujahid A.A.; Mandefiel, Laura; Bland, Martin; Aebischer, Toni; Gabe, Rhian; Layton, Alison M.; Lacey, Charles J.N.; Kaye, Paul M.; Musa, Ahmed M.

Post-kala-azar dermal leishmaniasis (PKDL) is a chronic, stigmatizing skin condition occurring frequently after apparent clinical cure from visceral leishmaniasis. Given an urgent need for new treatments, we conducted a ...